For the first time, researchers have a specific target for the treatment of these conditions by indentifying an immune molecule called
A great deal of work has been done on the genetic predisposition to autoimmune disease over the past 10 years. However, it has been very difficult to develop effective treatments because a large number of genes each make a very small contribution to the development of these diseases.
Inflammatory bowel disease (IBD) alone affects 240,000 people in the UK and costs the NHS £700 million every year. It causes debilitating symptoms, impaired quality of life and serious complications including cancer, bowel blockage and bowel perforation. Many patients will be hospitalised and some will need to undergo disfiguring operations.
This study was supported by grants awarded by the NIHR BRC at Guy’s and St Thomas’ NHS Foundation Trust and King’s College Lodnon, Wellcome Trust, the Medical Research Council and the Biotechnology and Biological Sciences Research Council (BBSRC).